Von Willebrand Disease Treatment Market - Growth, Trends, and Forecast (2020 - 2025)
|出版商||Mordor Intelligence LLP||商品編碼||921911|
|出版日期||內容資訊||英文 111 Pages
|全球血友病病治療市場:成長，趨勢，及預測(2020年∼2025年) Von Willebrand Disease Treatment Market - Growth, Trends, and Forecast (2020 - 2025)|
|出版日期: 2020年01月01日||內容資訊: 英文 111 Pages||
According to the World Federation of Hemophilia, Von Willebrand disease is a very common bleeding defect. People suffering from the Von Willebrand disease have a defect in the protein present in their blood, known as the Von Willebrand factor. The Von Willebrand factor helps the cells present in the blood vessel called platelets, to form a clot to control and stop bleeding.
Von Willebrand disease is a frequent inherited disorder that affects both sexes. The growing healthcare expenditure and rising number of assistance programs for patients who need treatment of von Willebrand disease are expected to drive the von Willebrand disease treatment market. However, the lack of awareness about the disease and the high cost of the treatment is among the major barrier to the growth of this market over the forecast period.
As per the scope of the report, Von Willebrand disease (VWD) is a genetic disorder that delays the process of blood clotting. It is generally caused by missing or defective von Willebrand factor (VWF), a clotting protein. VWF binds factor VIII, a key clotting protein, and platelets in blood vessel walls. Desmopressin is a common drug used for the treatment of Von Willebrand disease, which is an antidiuretic hormone that triggers the release of VWF into the plasma and may increase levels of factor VIII.
Desmopressin Segment is Expected to Register a Significant Growth in the Forecast Years
By treatment type, the market has been segmented into Desmopressin, Replacement Therapies, Clot-stabilizing Medications, and others. Desmopressin stimulates the release of VWF from cells, which also increases FVIII. This is considered to be the most preferred treatment option for patients with type 1, who account for approximately 70% to 80% of cases.
Type 1 and some subtypes of type 2 von Willebrand disease have more effective results with desmopressin as compared to the other types and thus it is expected to grow during the forecast period. In addition, growing healthcare expenditure and a large patient pool also contribute to the growth of the von Willebrand disease treatment market.
North America Leads the Von Willebrand Disease Treatment Market
North America is found leading the market owing to the upsurge in the demand for progressive treatment options, early adoption of new technologies and an increase in patient assistance programs. According to the National Hemophilia Foundation, VWD is the most common bleeding disorder, affecting up to 1% of the US population.
Europe and the Asia Pacific are followed next after North America owing to the presence of a diversified patient pool, emerging economies, and a rise in the collaboration of domestic and international companies in these regions, thus driving this market.
The von willebrand disease treatment market is competitive and many of the global players are into the market. For instance - Bayer AG, CSL Behring, Ferring Pharmaceuticals, Grifols, Octapharma AG, Pfizer, Sanofi, Sun Pharmaceutical and Takeda are providing these products across the globe.